An Open Label Extension Study of BMS-911543 In Subjects With Myelofibrosis


About this study

The purpose of this study is to provide patients with myleofibrosis (MF) who participated in study CA215001 access to BMS-911543.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients currently enrolled in study CA215001 and receiving benefit and tolerating BMS-911543.  NOTE: Patients will continue therapy at their doctor’s discretion until November 30, 2016 or until the patients develop progressive disease or unacceptable toxicity criteria, whichever occurs first.
  • Provide informed written consent.
  • Age ≥ 18 years 
  • Willing to return to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).

Exclusion Criteria:

  • Any of the following:
    • Pregnant women
    • Nursing women
    • Men or women of childbearing potential who are unwilling to employ adequate contraception

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Animesh Pardanani, M.B.B.S., Ph.D.

Closed for enrollment

Contact information:

Research Information Center


More information


Publications are currently not available

Mayo Clinic Footer